Skip to main content

TXMD

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

TXMD Price
Price Chart

Forward-looking statistics

Beta
1.79
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees113
Market cap$24.2M

Fundamentals

Enterprise value—
Revenue—
Revenue per employee—
Profit margin—
Debt to equity—

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)—
Avg trading volume (10 day)—
Put-call ratio—

Macro factor sensitivity

Growth+1.7
Credit+6.2
Liquidity-0.2
Inflation-4.3
Commodities-0.6
Interest Rates-1.3

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio4.26
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings dayMarch 30, 2024
Next dividend day—
Ex. dividend day—

News

TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying

The Dow Jones index closed higher by more than 450 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.

Benzinga (August 26, 2024)
All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy

TherapeuticsMD (TXMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (April 14, 2023)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free